Proposed Regulatory Fees and Licensing Framework for Pharmacy Ownership in Queensland
On 3 May 2018, Queensland Parliament referred an inquiry into the establishment of a pharmacy council and transfer for pharmacy ownership in Queensland (inquiry) to the Health, Communities, Disability Services and Domestic and Family Violence Prevention Committee (committee). The committee's Report No. 12, 56th Parliament - Inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Queensland (the committee report) was tabled in Parliament on 16 October 2018. The Committee made 11 recommendations relating to the establishment of a pharmacy council, regulation of pharmacy ownership, changes to ownership legislation and improved transparency of compliance outcomes in the pharmacy industry.
The government response to the committee’s report, accepted in full or in principle all recommendations.
The Consultation Regulatory Impact Statement (Consultation RIS) (PDF 955 kB) discusses whether to:
- establish a new licensing framework to monitor, and where necessary, enforce compliance with the ownership requirements in the PBO Act;
- prescribe licensing fees as part of the new licensing framework;
- prescribe a fee to fund the Queensland Pharmacy Council (Council) as an advisory body to provide advice to the Deputy Premier, Minister for Health and Minister for Ambulance Services (the Deputy Premier) and Queensland Health about the administration and enforcement of compliance with the PBO Act, and to make recommendations to Queensland Health about the transfers of pharmacy businesses, as required; and
- publish a register containing information about the ownership and location of pharmacy businesses.
Queensland Health is undertaking this assessment and public consultation on behalf of the Queensland Government. The Consultation RIS provides an overview of proposed options to address the committee’s recommendations and outlines some potential regulatory reform options for feedback.
We will aim to conduct a number of consultations sessions, which we anticipate will be held virtually and / or via teleconference. You can express your interest in attending a session by using the link below.
Responding to the Consultation RIS
While submissions may be lodged electronically or by post, electronic lodgment is preferred. For accessibility reasons, please submit responses via email in either Word, RTF or PDF formats.
The public consultation closing date for submissions has been extended. Submissions are open until 5pm Friday 6th November 2020.
How to respond
Address written submissions to:
Chief Medical Officer & Healthcare Regulation Branch
Pharmacy Inquiry Response Program
GPO Box 48
Brisbane, Queensland 4001